← All trials
NCT02509273
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2016
- Primary completion
- Jul 1, 2017
- Completion date
- Nov 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Erlangen-NurembergLead sponsor
- University of TartuCollaborator
- Bambino Gesù Hospital and Research InstituteCollaborator
- Therakind LtdCollaborator
- Gianni Benzi Pharmacological Research FoundationCollaborator
- Vereniging Samenwerkende Ouder- En PatientenorganisatiesCollaborator
- European CommissionCollaborator
- Charles UniversityCollaborator
- University of LondonCollaborator
- Karolinska InstituteCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.